These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 16507211)

  • 21. Disseminated eruptive giant mollusca contagiosa in an adult psoriasis patient during efalizumab therapy.
    Weisenseel P; Kuznetsov AV; Flaig M; Prinz JC
    Dermatology; 2008; 217(1):85-6. PubMed ID: 18446030
    [TBL] [Abstract][Full Text] [Related]  

  • 22. T-cell non-Hodgkin's lymphomas reported to the FDA AERS with tumor necrosis factor-alpha (TNF-α) inhibitors: results of the REFURBISH study.
    Deepak P; Sifuentes H; Sherid M; Stobaugh D; Sadozai Y; Ehrenpreis ED
    Am J Gastroenterol; 2013 Jan; 108(1):99-105. PubMed ID: 23032984
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Osteomyelitis occurring during infliximab treatment of severe psoriasis.
    Sri JC; Tsai CL; Deng A; Gaspari AA
    J Drugs Dermatol; 2007 Feb; 6(2):207-10. PubMed ID: 17373180
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Complications and adverse reactions in the use of newer biologic agents.
    Callen JP
    Semin Cutan Med Surg; 2007 Mar; 26(1):6-14. PubMed ID: 17349557
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Development of new-onset psoriasis in a patient receiving infliximab for treatment of rheumatoid arthritis.
    Chan CY; Browning JC; Larsen F; Hsu S
    Dermatol Online J; 2008 Sep; 14(9):12. PubMed ID: 19061594
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Diffuse large B-cell lymphoma in a patient with rheumatoid arthritis treated with infliximab and methotrexate.
    Nakashima C; Tanioka M; Takahashi K; Miyachi Y
    Clin Exp Dermatol; 2008 Jul; 33(4):437-9. PubMed ID: 18485021
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Case reports: efalizumab-associated lymphoproliferative disease.
    Bommakanti S; Patil A; Eshoa C; Chitambar CR
    J Drugs Dermatol; 2007 Jun; 6(6):646-8. PubMed ID: 17668531
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Tocilizumab-induced erythroderma.
    Nakamura M; Tokura Y
    Eur J Dermatol; 2009; 19(3):273-4. PubMed ID: 19251575
    [No Abstract]   [Full Text] [Related]  

  • 29. Development of psoriasis after B cell depletion with rituximab.
    Dass S; Vital EM; Emery P
    Arthritis Rheum; 2007 Aug; 56(8):2715-8. PubMed ID: 17665440
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Risk of serious infections and malignancies with anti-TNF antibody therapy in rheumatoid arthritis.
    Hochman D; Wolff B
    JAMA; 2006 Nov; 296(18):2203; author reply 2203-4. PubMed ID: 17090763
    [No Abstract]   [Full Text] [Related]  

  • 31. Risk of serious infections and malignancies with anti-TNF antibody therapy in rheumatoid arthritis.
    Callegari PE; Schaible TF; Boscia JA
    JAMA; 2006 Nov; 296(18):2202; author reply 2203-4. PubMed ID: 17090762
    [No Abstract]   [Full Text] [Related]  

  • 32. Risk of serious infections and malignancies with anti-TNF antibody therapy in rheumatoid arthritis.
    Costenbader KH; Glass R; Cui J; Shadick N
    JAMA; 2006 Nov; 296(18):2201; author reply 2203-4. PubMed ID: 17090761
    [No Abstract]   [Full Text] [Related]  

  • 33. Long-term continuous efalizumab therapy in patients with moderate to severe chronic plaque psoriasis: updated results from an ongoing trial.
    Gottlieb AB; Hamilton T; Caro I; Kwon P; Compton PG; Leonardi CL;
    J Am Acad Dermatol; 2006 Apr; 54(4 Suppl 1):S154-63. PubMed ID: 16488337
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Onset of psoriatic arthritis in patients treated with efalizumab for moderate to severe psoriasis.
    Viguier M; Richette P; Aubin F; Beylot-Barry M; Lahfa M; Bedane C; Delesalle F; Richard-Lallemand MA; Delaporte E; Dubertret L; Bardin T; Bachelez H
    Arthritis Rheum; 2008 Jun; 58(6):1796-802. PubMed ID: 18512820
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Peritoneal tuberculosis complicated by immune reconstitution inflammatory syndrome in a patient treated with infliximab?: a case for adjuvant immunosuppressive therapy.
    Szerszen A; Gupta S; Seminara D; Jarrett M; Goldstein M
    J Clin Rheumatol; 2009 Dec; 15(8):417-8. PubMed ID: 19956004
    [No Abstract]   [Full Text] [Related]  

  • 36. Subcutaneous panniculitis-like T cell lymphoma in a HIV positive patient.
    Joseph LD; Panicker VK; Prathiba D; Damodharan J
    J Assoc Physicians India; 2005 Apr; 53():314-6. PubMed ID: 15987019
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Recommendations for incorporating biologicals into management of moderate to severe plaque psoriasis: individualized patient approaches.
    Langley RG; Ho V; Lynde C; Papp KA; Poulin Y; Shear N; Toole J; Zip C
    J Cutan Med Surg; 2006; 9 Suppl 1():18-25. PubMed ID: 16633860
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Biologics in the treatment of psoriasis].
    Dissemond J; Grabbe S
    MMW Fortschr Med; 2006 Sep; 148(38):42-4. PubMed ID: 17036963
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Risk of serious infections and malignancies with anti-TNF antibody therapy in rheumatoid arthritis.
    Okada SK; Siegel JN
    JAMA; 2006 Nov; 296(18):2201-2; author reply 2203-4. PubMed ID: 17090760
    [No Abstract]   [Full Text] [Related]  

  • 40. Efalizumab: new drug. Plaque psoriasis: too many unknowns.
    Prescrire Int; 2006 Feb; 15(81):8-11. PubMed ID: 16548097
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.